USFDA Issues Three Form 483 Observations for Gufic Biosciences' Indore Facility
Gufic Biosciences Ltd 路 Others (Uncategorized) 路 24 Oct 2026, 2:11 am
USFDA Issues Three Form 483 Observations for Gufic Biosciences' Indore Facility The USFDA conducted a Pre-Approval Inspection (PAI) at Gufic Biosciences Limited's manufacturing facility located in Indore, Madhya Pradesh, from 15th Oct'26 to 23rd Oct'26. Upon concluding the inspection, the regulator issued Form FDA 483 with three observations. The company stated it will work closely with the USFDA and remains committed to addressing all observations comprehensively within the stipulated timeframe.
Original exchange filing (PDF)
More announcements from Gufic Biosciences Ltd
- Intimation of Audio Recording of Earnings Conference Call held on November 16, 2026 at 04:30 p.m. is attached herewith 路 17 Nov 2026
- Investor Presentation is attached herewith 路 15 Nov 2026
- Intimation for appointment of Additional Director (Non-Executive Independent Director) of the Company is attached herewith. 路 15 Nov 2026
- Gufic Biosciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 15 Nov 2026
- Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year Ended September 30, 2026 is attached herewith 路 15 Nov 2026
- Outcome of the Board of Directors Meeting held on Saturday, November 14, 2026 is attached herewith. 路 15 Nov 2026
- Intimation of Environmental, Social and Governance (''ESG'') Rating is attached herewith 路 13 Nov 2026
- Intimation of Earnings Conference Call scheduled to be held on November 16, 2026 is attached herewith 路 16 Nov 2026
